Publication Name	World Journal of Hepatology
Manuscript ID	89977
Country	Italy

Received	2023-11-19 11:19
Peer-Review Started	2023-11-19 11:19
To Make the First Decision
Return for Revision	2023-12-08 17:47
Revised	2024-01-03 15:25
Second Decision	2024-01-24 02:46
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-01-24 07:59
Articles in Press	2024-01-24 07:59
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-02-01 01:12
Publish the Manuscript Online	2024-02-27 11:58

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Can rifaximin for hepatic encephalopathy be discontinued during broad-spectrum antibiotic treatment?
Manuscript Source	Invited Manuscript
All Author List	Chien-Hao Huang and Piero Amodio
Funding Agency and Grant Number	Funding Agency Grant Number the Chang Gung Medical Research Project CMRPG3M1931-1932 the National Science and Technology Council MOST 110-2314-B-182A-093- and NMRPG3L0331
Corresponding Author	Piero Amodio, Doctor, MD, Academic Editor, Additional Professor, Department of Clinical and Experimental Medicine, University of Padua, Via Giustiniani, 2, Padova 35122, Italy. piero.amodio@unipd.it
Key Words	Rifaximin discontinuation; Hepatic encephalopathy; Broad-spectrum antibiotics; Crit-ically ill; Medical intensive care unit; Pharmacist-driven protocol
Core Tip	Rifaximin (RFX) is a gut-restricted adjunct to lactulose that minimizes hepatic encephalopathy (HE) recurrence with minimal systemic absorption. Despite established benefits, limited Food and Drug Administration approval for acute HE raises concern about its use in treating acute overt HE. Recent evidence challenges the routine use of RFX with broad-spectrum antibiotics, emphasizing their class-specific effects in critically ill patients. The study sheds light on the safety of discontinuing RFX during broad-spectrum antibiotic therapy in intensive care unit patients with liver disease and HE, and also prompts reevaluation of the role of RFX amid the overlapping antibiotic activity. This evidence underscores the need for further investigations to optimize the management of both HE and systemic infections in patients with liver disease, including those who are not critically ill.
Publish Date	2024-02-27 11:58
Citation	Huang CH, Amodio P. Can rifaximin for hepatic encephalopathy be discontinued during broad-spectrum antibiotic treatment? World J Hepatol 2024; 16(2): 115-119
URL	https://www.wjgnet.com/1948-5182/full/v16/i2/115.htm
DOI	https://dx.doi.org/10.4254/wjh.v16.i2.115

Full Article (PDF)	WJH-16-115-with-cover.pdf
Full Article (Word)	WJH-16-115.docx
Manuscript File	89977_Auto_Edited-YJP.docx
Answering Reviewers	89977-Answering reviewers.pdf
Audio Core Tip	89977-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	89977-Conflict-of-interest statement.pdf
Copyright License Agreement	89977-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	89977-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate	89977-Language certificate.pdf
Peer-review Report	89977-Peer-review(s).pdf
Scientific Misconduct Check	89977-Bing-Li L-2.png
Scientific Editor Work List	89977-Scientific editor work list.pdf